PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10503166-21	1998	Subsequent to this study, a trial of lentinan in combination with didanosine (ddI) showed a mean increase of 142 CD4 cells/mm3 over a twelve month period, in contrast to a decrease in CD4 cells in patients on ddI alone (Gordon et al.	Lentinan	37-45	CD4 molecule	Homo sapiens	113-116	
11205205-5	2000	RESULTS: After LNT treatment, CD4+ IFN-gamma+ T-cell percentages increased significantly (p < 0.05), whereas CD4+ IL-4+ T-cell and CD4+ IL-6+ T-cell percentages decreased significantly (p < 0.02).	Lentinan	15-18	CD4 molecule	Homo sapiens	30-33	
10458542-7	1999	The preoperative administration of lentinan for patients undergoing CPB ameliorated the impairment of natural killer activity and promoted the rapid recovery of CD4-positive cells.	Lentinan	35-43	CD4 molecule	Homo sapiens	161-164	
30460541-9	2020	Meanwhile, the percentage of CD4+ CD25+ Tregs is down-regulated, leading to a shift in the inflammatory status from Th2 to Th1 in NSCLC patients treated with lentinan.	Lentinan	158-166	CD4 molecule	Homo sapiens	29-32	
10503166-21	1998	Subsequent to this study, a trial of lentinan in combination with didanosine (ddI) showed a mean increase of 142 CD4 cells/mm3 over a twelve month period, in contrast to a decrease in CD4 cells in patients on ddI alone (Gordon et al.	Lentinan	37-45	CD4 molecule	Homo sapiens	184-187